CER-001

DB18538Investigational

CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.

Code names: CER-001

What you can answer from here — as of April 23, 2025

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of CER-001, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account